ncRNA basic information
ncRNA ID:
MI0000447/MI0000727
ncRNA Database:
miRBase
ncRNA Name:
miR-128
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
MUC1 and BMI1
ncRNA Pathway:
PI3K/AKT pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)
Drug Name:
Paclitaxel
Drug Method:
In the study, we showed that CSCs have significantly higher expression levels of BMI-1, MUC1-C, stemness proteins, signaling factors, and higher malignancy compared with normal tumor cells. After transfection with miR-128, the BMI-1 and MUC1-C levels in CSCs were suppressed. When miR-128 was stably expressed in PTX-resistant lung cancer stem cells, the cells showed decreased proliferation, metastasis, self-renewal, migration, invasive ability, clonogenicity, and tumorigenicity in vitro and in vivo and increased apoptosis compared with miR-NC (negative control) CSCs. Furthermore, miR-128 effectively decreased the levels of Beta-catenin and intracellular signaling pathway-related factors in CSCs. MiR-128 also decreased the luciferase activity of MUC1 reporter constructs and reduced the levels of transmembrane MUC1-C and BMI-1. These results suggested miR-128 as an attractive therapeutic strategy for PTX-resistant lung cancer via inhibition of BMI-1 and MUC1-C.
Drug Response:
sensitive
Cancer basic information
Cancer:
lung cancer
Tissue/Cell:
cell line (A549,A549/PTX)
Other information
Title:
MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells.
Journal:
Oncotarget
Published:
2017
PubMed ID:
29299167